![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Canada's National Research Council in Vaccines Deal
Canada's National Research Council in Vaccines Deal
US-based firm BioVeris has announced an agreement with Canada's state-funded National Research Council on two candidate vaccines. Under the deal, the National Research Council will receive a minimum US$10,000 annual royalty and undisclosed royalties on product sales. In exchange, BioVeris will now have worldwide, exclusive marketing and sales rights on the products, which protect against group B streptococcus Type II and Type V, and group B meningococcus. The former bacterium is a leading cause of sepsis, pneumonia and meningitis in newborn babies, and is fatal in about 20% of adult sufferers.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
18Jul
-
21Oct